Efficacy News and Research

RSS

FDA issues warning letters to companies illegally selling products that claim to cure cancer

As part of the U.S. Food and Drug Administration's ongoing efforts to protect consumers from health fraud, the agency today issued warning letters to four companies illegally selling products online that claim to prevent, diagnose, treat, or cure cancer without evidence to support these outcomes.

2 Nov 2017

Simple hand hygiene procedures can be key to improve compliance rates

As the threat of AMR grows, hand hygiene compliance will become critical, but it is often difficult for healthcare environments to maintain. One of the best ways to improve compliance rates is to make the procedures quick and easy to follow – without undermining their efficacy.

2 Nov 2017

Understanding obesity-cancer link to develop effective prevention strategies

In 2012, about 28,000 new cases of cancer in men (3.5%) and 72,000 in women (9.5%) were due to overweight or obesity in the United States alone. There is an urgent need for research that focuses on the cancer-promoting effects of obesity as it's the leading preventable cause of cancer for women and the second for men.

1 Nov 2017

Topical gel made from blood pressure pills holds great promise in healing chronic wounds

An international team of researchers led by Johns Hopkins has shown that a topical gel made from a class of common blood pressure pills that block inflammation pathways speeds the healing of chronic skin wounds in mice and pigs.

1 Nov 2017

PARP inhibitors may have efficacy in selected TNBC patients outside of germline BRCA mutation

The investigational PARP inhibitor talazoparib caused regression of patient-derived xenografts (PDXs) of triple-negative breast cancers (TNBC) that had BRCA mutations and also those that did not have BRCA mutations but had other alterations in DNA damage-repair pathways.

1 Nov 2017

GHIT Fund announces US$16.7 million to support development of new drugs, vaccines and diagnostics

The Global Health Innovative Technology Fund, a unique Japanese public-private partnership formed to battle infectious diseases around the globe, today announced US$16.7 million to support development of new compounds for fighting malaria and tuberculosis, a leishmaniasis vaccine and drug, and a treatment for a long-ignored flesh-eating infection.

31 Oct 2017

Researchers caution against using antibodies to prevent HIV transmission from mother to child

HIV+ mothers who possess a strong neutralizing antibody response may be more likely to pass the virus on to her infant through breast feeding. In addition, infants born to mothers with a strong antibody response are significantly more likely to have a serious illness or death, regardless of whether or not they acquire the virus.

31 Oct 2017

New treatment reduces disease burden in patients with rare dermatologic condition

A new treatment for a rare and often incurable condition called dermatomyositis (DM) reduced the severity of the disease in patients whose DM was resistant to other therapies.

31 Oct 2017

Abbott receives CE Mark for newest generation of drug-eluting XIENCE coronary stent system

Abbott today announced it received CE Mark for XIENCE Sierra, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system.

31 Oct 2017

SU2C and its collaborators announce four teams to intercept cancer at earliest stages

Stand Up To Cancer, joined by the Lustgarten Foundation for Pancreatic Cancer Research, LUNGevity, and the American Lung Association, announced today four teams of top researchers who will carry out an attack on cancers of the lung and pancreas using a radical new approach of “interception” of cancers at very early stages, when they can be more successfully treated.

31 Oct 2017

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

Novartis today announced full results from the positive Phase III PARADIGMS study, investigating the safety and efficacy of Gilenya (fingolimod) vs. interferon beta-1a, in children and adolescents (ages 10 to 17) with multiple sclerosis (MS).

30 Oct 2017

Sunovion announces results from Phase 3 clinical study of new drug in children, adolescents with bipolar depression

Sunovion Pharmaceuticals Inc. today announced post-hoc analysis results of a positive Phase 3 placebo-controlled clinical study, as well as interim data from a long-term open-label extension study evaluating Latuda (lurasidone HCI) in children and adolescents (10 to 17 years of age) with major depressive episodes associated with bipolar I disorder (bipolar depression).

28 Oct 2017

Clinical trial shows promising results for treatment of patients with recurrent high-grade glioma

New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment.

28 Oct 2017

Novel consortium aims to create new paradigm of cancer drug discovery

Scientists from two U.S. national laboratories, industry and academia today launched an unprecedented effort to transform the way cancer drugs are discovered by creating an open and sharable platform that integrates high-performance computing, shared biological data from public and industry sources and emerging biotechnologies to dramatically accelerate the discovery of effective cancer therapies.

27 Oct 2017

Genome-wide molecular tests can guide treatment in recurrent glioblastoma, study shows

Several patients with recurring glioblastoma, a deadly brain cancer, survived for more than a year in a clinical trial believed to be the first to use comprehensive DNA and RNA sequencing of a patient's tumor to inform treatment for these patients in real-time.

27 Oct 2017

Study reveals how NET intervention can alleviate stress from traumatic cancer-related memories

Patients diagnosed and treated for a long-term potentially fatal diseases such as cancer, can accumulate distressing and traumatic experiences along the way.

27 Oct 2017

Sleeper cells in cancerous tumors can be destroyed if they possess specific defects

In many metastasized types of cancer, disseminated tumors grow back despite successful chemotherapy. As a research team under the direction of the University of Bern, Switzerland, has now discovered, this is because of isolated cancer cells that survive the chemotherapy due to a phase of dormancy.

27 Oct 2017

Education may help increase awareness of HPV risk and vaccination rates in college-age men

Male collegiate athletes have high rates of risk factors for infection with the cancer-causing human papillomavirus (HPV), but have low HPV vaccination rates and low awareness of their personal health risks, according to a study in the November issue of The Nurse Practitioner, published by Wolters Kluwer.

26 Oct 2017

IBN researchers create DNA technology with two new genetic alphabets

Just like how alphabets are strung together to form words, our DNA is also strung together by alphabets to encode proteins. Our DNA contains only 4 natural genetic alphabets - A, C, G and T, which hold the blueprint for the production of proteins that make our bodies work.

26 Oct 2017

Study shows efficacy of antipsychotic as adjunctive therapy for gastroparesis in emergency department

Haloperidol is an effective first-line agent in combination with standard analgesic and antiemetic agents for the treatment of gastroparesis in the emergency department.

26 Oct 2017

Efficacy News and Research

FDA issues warning letters to companies illegally selling products that claim to cure cancer

Simple hand hygiene procedures can be key to improve compliance rates

Understanding obesity-cancer link to develop effective prevention strategies

Topical gel made from blood pressure pills holds great promise in healing chronic wounds

PARP inhibitors may have efficacy in selected TNBC patients outside of germline BRCA mutation

GHIT Fund announces US$16.7 million to support development of new drugs, vaccines and diagnostics

Researchers caution against using antibodies to prevent HIV transmission from mother to child

New treatment reduces disease burden in patients with rare dermatologic condition

Abbott receives CE Mark for newest generation of drug-eluting XIENCE coronary stent system

SU2C and its collaborators announce four teams to intercept cancer at earliest stages

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

Sunovion announces results from Phase 3 clinical study of new drug in children, adolescents with bipolar depression

Clinical trial shows promising results for treatment of patients with recurrent high-grade glioma

Novel consortium aims to create new paradigm of cancer drug discovery

Genome-wide molecular tests can guide treatment in recurrent glioblastoma, study shows

Study reveals how NET intervention can alleviate stress from traumatic cancer-related memories

Sleeper cells in cancerous tumors can be destroyed if they possess specific defects

Education may help increase awareness of HPV risk and vaccination rates in college-age men

IBN researchers create DNA technology with two new genetic alphabets

Study shows efficacy of antipsychotic as adjunctive therapy for gastroparesis in emergency department

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News